Table 1.

Significantly prolonged survival of mice with established tumors following administration of mAbs to CD137/PD-1/CTLA-4 or to CD137/PD-1/CTLA-4/CD19

Survival (d, M ± SEM)
Tumor modelControlThree-mAb i.t.Three-mAb i.p.Four-mAb i.t.Four-mAb i.p.
SW1 (25 mm2, n = 108)14.5 ± 0.9 (0/38)a107.2 ± 8.6d (26/40)61.3 ± 11f (5/15)157.9 ± 9.2d,f(14/15)NT
SW1 (80 mm2, n = 15)16 ± 1.3 (0/5)50.6 ± 9.2c (0/5)NT111 ± 24.1c,e (3/5)NT
B16 (25 mm2, n = 55)8.6 ± 0.7 (0/20)51.3 ± 19.4c (3/10)NT121.5 ± 16.5d,e (14/20)40.6 ± 24.9g (1/5)
B16 (80 mm2, n = 35)9.5 ± 0.9 (0/15)29.5 ± 10.4b (1/10)NT77 ± 18.9d,e (5/10)NT
TC1(25 mm2, n = 45)10.4 ± 0.8 (0/15)61 ± 19.3b (4/15)NT94.5 ± 21.5d,e (7/15)NT
  • aSurvival (tumor free)/number of treated mice 120 days after the first treatment.

  • bP < 0.05; cP < 0.01; dP < 0.001, compared with the control group; eP < 0.05; fP < 0.01, compared with the three-mAb i.t. group; gP < 0.05, compared with the four-mAb i.t. group.